Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

recurrent Langerhans Cell Histiocytosis

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of recurrent, refractory, or progressive low-risk disease: single-system or multisystem LCH

Broader topic: Langerhans Cell Histiocytosis

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of recurrent, refractory, or progressive low-risk disease: single-system or multisystem LCH

    Study evidence for this setting

    6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT01273766 · Registry condition search · Scope: unclear

    Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

    3 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT03096782 · Registry condition search · Scope: unclear

    Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

    3 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213665 · Source cited / selected · Scope: unclear

    Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213678 · Registry condition search · Scope: unclear

    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATC

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213704 · Registry condition search · Scope: unclear

    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03698994 · Registry condition search · Scope: unclear

    Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice